Breast Cancer Foundation NZ
TAPISTRY
This study will evaluate the safety and efficacy of targeted therapies or immunotherapy in participants with have inoperable tumours that have a genetic mutation.
The purpose of this clinical trial is to compare the effects, good or bad, of different targeted therapies and immunotherapies in patients with solid tumors that cannot be surgically removed and show specific biomarkers.
Who is it for?
To be able to take part in this clinical trial, you must have been diagnosed with solid tumors that cannot be surgically removed and show one of the specific biomarkers that are being tested in this study:
- ROS1 fusion-positive tumors
- NTRK1/2/3 fusion-positive tumors
- ALK fusion-positive tumors
- TMB-high tumors
- AKT1/2/3 mutant-positive tumors
- HER2 mutant-positive tumors
- MDM2-amplified, TP53 wild-type tumors
- PIK3CA multiple mutant-positive tumors
Study details
If you join this clinical trial, you will be entered into one of eight groups, depending on which biomarker your solid tumor has:
- Group A: People with ROS1 fusion-positive tumors. You will receive entrectinib as capsules to take by mouth with or without food every day for as long as it can help you
- Group B: People with NTRK1/2/3 fusion-positive tumors. You will receive entrectinib as capsules to take by mouth with or without food every day, for as long as it can help you
- Group C: People with ALK fusion-positive tumors. You will receive alectinib as capsules to take twice a day with food, for as long as it can help you
- Group D: People with TMB-high tumors. You will receive atezolizumab through a drip as an infusion into the vein once every 3 weeks, for as long as it can help you
- Group E: People with AKT1/2/3 mutant-positive tumors. You will receive ipatasertib as a tablet to take once a day with or without food, for as long as it can help you
- Group F: People with HER2 mutant-positive tumors. You will receive transtuzumab emtansine through a drip as an infusion into the vein once every 3 weeks, for as long as it can help you
- Group G: People with MDM2-amplified, TP53 wild-type tumors. You will receive idasanutlin as a tablet to take once a day for 5 days. This 5-day treatment will repeat every 28 days and will continue for as long as it can help you
- Group H: People with PIK3CA multiple mutant-positive tumors. You will receive GDC-0077 as a tablet to take once a day, for as long as it can help you
This clinical trial is ‘open-label’, which means that everyone involved will know which group they are in and what treatment they are receiving. Participants will be given the clinical trial treatment for as long as it can help them.
New Zealand
Christchurch Hospital (not yet recruiting)
Australia
Peter MacCallum Cancer Centre, Melbourne
St Vincent's Hospital, Sydney
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Advanced Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.